Vaccines prepared from Friend leukaemia virus envelope and core polypeptides were compared for their efficiency in preventing erythroleukaemia in mice. High doses (100 gg) of gp85, the micellar complex of the envelope polypeptides gp70 and pl5E, completely protected STU mice. The same dose of purified gp70 still protected about 80~ of the animals, while pl5E did not affect the cumulative mortality. The internal viral polypeptide p30 was ineffective. Serological examination indicated that immunity against death from leukaemia was mediated by specific antibodies. These leukaemia-preventing antibodies were predominantly induced by immunization with the gp70 env gene product, since pl5E showed only minor protection. Glycoprotein gp70, however, was more effective when given as the gp85 micellar complex. An even more potent vaccine was obtained when gp70 was coupled to keyhole limpet haemocyanin (KLH) by glutaraldehyde. Ten gg gp70 coupled to KLH was enough to save more than 90~ of Friend leukaemia virus-infected mice from erythroleukaemia.
INTRODUCTION
Polypeptides gp70, p15E and p30 are major structural polypeptides of murine leukaemia viruses. The glycosylated gp70 is exposed on the viral envelope and on the surface of virusproducing cells, while pl5E, an unglycosylated membrane polypeptide, attaches gp70 to the lipid bilayer of the cellular and viral membrane Schwarz et al., 1976; Schneider & Hunsmann, 1978) . Polypeptide p30, agag gene product, is the predominant protein of the inner core of these retroviruses (Gregoriades & Old, 1969; Sch~ifer et al., 1969; Strand & August, 1974) .
The two envelope polypeptides gp70 and p l 5E fulfil important biological functions of these viruses such as adsorption onto and penetration into receptor-carrying host cells (Delarco & Todaro, 1976; Robinson et al., 1980) . Furthermore, they induce neutralizing and cytotoxic antibodies (Hunsmann et al., , 1975 Ihle & Hanna, 1977) . Previously, we have shown that immunization with appropriate doses of Friend leukaemia virus (FLV)gp85 rosettes, the miceUar complex of gp70 and pl5E, protected mice from virus-induced erythroleukaemia (Hunsmann et al., 1981) . In this study we analysed separately the role in immunoprotection of each viral polypeptide and demonstrated that leukaemia-preventing antigenic determinants are restricted to gp70. Antibodies to p15E prolong the survival time, but cannot decrease the cumulative mortality after a long observation period. The high efficacy of gp85 complexes, which occur naturally on the viral surface, was improved by covalently linking gp70 to keyhole limpet haemocyanin (KLH). * Serum dilution (log~0) that binds radioactivity at levels three times the background value obtained with normal mouse serum. Sera were taken on the day before challenge with FLV.
t Standard deviations are given in parentheses.
by Schneider et al. (1979) . After reduction of gp85, gp70 and pl5E were purified by molecular sieve chromatography . The gp70-KLH conjugate was obtained by glutaraldehyde coupling (Kagan & Glick, 1979; Bayer et al., 1984) . Polypeptide gp70 and a triple amount of KLH (Paesel, Frankfurt, F.R.G.) were mixed in phosphate-buffered saline (PBS) and incubated at room temperature with a final concentration of 0-2~ glutaraldehyde for 1 h. Free glutaraldehyde was eliminated by extensive dialysis against PBS. The major viral core protein p30 was isolated from FLV by ion-exchange chromatography on phosphocellulose (Strand & August, 1976) .
Polypeptides were analysed by SDS-polyacrylamide slab gel electrophoresis (Studier, 1973) under reducing conditions, using a discontinuous buffer system (Laemmli, 1970) .
Preparation and application of the vaccines. Solutions of purified viral polypeptides were emulsified with an equal volume of incomplete Freund's adjuvant (ICFA). Female STU mice, 8 to 12 weeks old, were immunized four times at 3-week intervals (Hunsmann et al., 1981) . Serum samples were taken before and several times after challenge. Antibody titres of these sera to FLV antigens used for immunization were determined by a radioimmunoprecipitation assay (RIPA) (Schneider et al., 1979; Hunsmann et al., 1981) . Briefly, viral polypeptides were iodinated by the chloramine-T method and incubated with serial dilutions of sera from individual mice. Antigen-antibody complexes were adsorbed onto Protein A-carrying bacteria (Sigma), washed and counted in a gamma counter (BF 5300; Berthold, Karlsruhe, F.R.G.). The serum dilution binding 10~ of acid-precipitable radioactive antigen was recorded as antibody titre.
To test for viraemia, concentrations of FLV p30 in sera taken after challenge were determined in a competition radioimmunoassay (Hunsmann et al., 1981) . The assay conditions were analogous to those in RIPA. An antiserum raised in a rabbit to FLV p30 was titrated with iodinated p30 antigen. The serum dilution binding 30 to 40~ of acid-precipitable antigen was used to construct the standard competition curve with unlabelled p30 and subsequent determinations of p30 concentrations in mouse sera. RESULTS 
AND DISCUSSION
Serum antibodies were specific for the immunizing FL V antigens STU mice were immunized with different amounts of purified FLV polypeptides. Sera taken before challenge from several mice immunized with 100 gg gp85, gp70, pl5E and p30 were examined by RIPA for their specificity. As demonstrated in Table 1 , the strongest reactivity was observed against the immunizing antigen. The envelope polypeptides were highly immunogenic in STU mice, while p30 elicited only a weak response. As expected, antisera to both gp70 and pl5E reacted with gp85, and the gp85 antiserum also precipitated gp70 and pl5E. However, no cross-reactivity between gp70 and pl5E sera was detected and p30 was only precipitated by its homologous serum. Thus, the envelope polypeptides induced a strong and specific immune response. These results indicate that the antigens were highly purified and had retained a potent antigenicity. This immunity was challenged by FLV inoculation.
Polypeptide gp85 is superior to gp70 and pl5E as a vaccine
It has been shown previously that immunization with purified FLV gp70 (Hunsmann et al., 1975) and to a lesser extent pl5E (Schiifer & Bolognesi, 1977) reduces the FLV-induced splenomegaly. To compare the efficiency of our vaccines, the survival time of individual mice after FLV challenge was recorded (Fig. 1) . Animals that had received only ICFA died between days 55 and 85 after FLV inoculation. In agreement with earlier results (Hunsmann et al., 1981) only animals of the group vaccinated with 100 gg FLV gp85 were totally protected against Friend leukaemia. However, 19~ (three out of 16) of mice immunized with 100 ~tg gp70 died; 100 ~tg p 15E only prolonged the 50 ~ survival time for approximately 40 days, but could not prevent the final death from leukaemia. Mice immunized with only 10 ~tg pl5E died as rapidly as controls. Whereas 10 ~tg gp85 conferred some protection, 10 ~tg or less of gp70 seemed to be inefficient as a vaccine. Immunization with p30 in the range of 0.1 to 100 ~tg also failed to protect. This could be explained by the low immunogenicity of p30 (Table 1) . Moreover, it underscores the earlier observation that FLV p30 determinants are not expressed on the viral and cellular surface Schwarz et al., 1976; Schneider & Hunsmann, 1978) .
Immune response to antigenic determinants on gp70 is primarily responsible for long-term protection
The protective capabilities of gp85 and gp70 vaccines are markedly superior to pl5E immunization (Fig. 1) . To understand this phenomenon better, the course of antibody response and viraemia after FLV challenge was examined in some mice from each group (Fig. 2) . All of the animals immunized with 100 ~tg gp85 and about 80~ of the mice immunized with 100 ~tg gp70 survived for longer than 250 days. These long-term survivors developed a strong response to gp85 and gp70 (Fig. 2) . The virus in these animals seemed to be suppressed by circulating, neutralizing antibodies. In animals 3.3, 3.4 and 3.5, a mild viraemic phase with a simultaneous depression of antibodies was observed. The recovery of the antibody titre probably determined survival of the animal (3.3, 3.4), while a decrease in the titre indicated a fatal course of the disease (3.5). None of the mice that died in the groups immunized with 10 ~tg gp85 and 10 ~tg gp70 had detectable antibodies and viraemia increased rapidly.
All animals immunized with 100 ~tg pl5E developed a strong antibody response which was, however, specific for the pl5E portion of gp85. No gp70 antibodies were found even in those mice surviving the FLV challenge for longer than 150 days. The pl5E antibodies apparently were only able to postpone the onset of viraemia or to slow down its development. Few mice died from leukaemia even later than 200 days after virus challenge. After an observation period of 250 days the cumulative mortality was in the range of the ICFA control group. The late course of the disease was similar in both the 10 ~tg and 100 ~tg groups. When pl5E antibodies disappeared, the animals rapidly developed a viraemia (animals 6.2 to 6.5). Cytotoxicity tests have shown that, in contrast to antibodies to gp70, antibodies to pl5E lyse virus-producing cells less efficiently Schneider & Hunsmann, 1978) and neutralize virus in vitro only in the presence of complement (Fischinger et al., 1976) . The STU strain, like other inbred mouse strains, is complement-deficient (our unpublished observation). This immunological situation most likely explains the incomplete protection of mice immunized with pl5E.
Although gp70 epitopes apparently induce immunity against Friend leukaemia, presentation of these epitopes in the gp85 complex is necessary for a potent vaccine. Nevertheless, we could not detect higher antibody titres after vaccination of mice with gp85 rosettes (Fig. 1, Table 1) . Thus, the gp85 complex, which is found on the viral surface as a natural aggregate, may induce antibodies with higher immunological activity, e.g. virus-neutralizing capacity.
Glutaraldehyde coupling of gp70 to KLH increases the potency of the vaccine against FL V
To evaluate whether artificial gp70 aggregates would show an equivalent immunological effect, a glutaraldehyde-coupled gp70-KLH conjugate was used as a vaccine. The KLH protein complex has a mol. wt. of 2 x 106 to 7 x 106 and is composed of monomers with a mol. wt. of about 70000 (Ellerton et al., 1983) . KLH is a strong immunogen and is therefore the preferred carrier for haptens, especially synthetic oligopeptides (Bittle et al., 1982; Bayer et al., 1984) . Glutaraldehyde coupling is a simple procedure for attaching such haptens to large proteins (Bayer et al., 1984) . Coupling of gp70 to KLH was controlled by SDS-PAGE (Fig. 3) . Glutaraldehyde formed large polypeptide complexes, which barely migrated into the gel.
Groups of 15 mice Were immunized with 1, 10 or 100 ~tg gp70 either coupled to a threefold amount of KLH or in the pure monovalent form. Further groups of 15 mice received a noncoupled mixture of gp70 and KLH in the same ratio as in the gp70-KLH complex. Two control groups were immunized either with KLH emulsified in ICFA or with ICFA alone. The course of immunization was surveyed by determination of antibody titres to gp70. Antibody titres of mice dnoa~ oql u! '~l~U!lS~aOluI "(ql~ '$!d) gI u° OL d~ lUOl sA°u°m ~r1001 qltax p~leU!00eA SletU!Ue jo immunized with 10 ~tg gp70-KLH, only one out of 15 mice died from leukaemia. Thus, the immunity of these mice was superior to that of animals immunized with 100 ~tg gp70 alone. A considerably higher mortality was found in mice immunized with 10 gg gp70 either alone or mixed with KLH. No protective immunization was detectable in any regimen involving only 1 gg gp70.
We conclude that the gp70 env gene product of FLV carries those antigenic determinants which protect mice against death from leukaemia. A corresponding result was found by Schwarz et al. (1984) in passive immunization experiments using polypeptide-specific antisera. The pure glycopolypeptide alone cannot protect all mice effectively. However, complete protection is attained by immunization with gp85 rosettes prepared from the viral membrane or, even more effectively, by glutaraldehyde-coupled gp70-KLH aggregates. Complexed gp70 may elicit higher affinity antibodies.
Presentation of antigens in large aggregates using KLH as a carrier will probably be even more important when oligopeptide fragments are used as protective vaccines. Knowledge about the mechanism of action and the efficacy of such vaccines in animal models is certainly valuable for the development of immunopreventive measures against human retroviruses (Hunsmann, 1985) . This work was supported by the Deutsche Forschungsgemeinschaft (SFB 31).
